Observational studyJournal of acquired immune deficiency syndromes (1999)2026
Brief Report: Dolutegravir-Based Therapy, Diet, Physical Activity, and Weight Gain: A 48-week Prospective Cohort in South Africa.
Observational study in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPeople with HIV (PWH) have experienced excess weight gain on tenofovir, lamivudine, and dolutegravir (TLD). The contribution of lifestyle behavior to this weight gain is poorly understood.
methodsThe Population Effectiveness of Dolutegravir Implementation in sub-Saharan Africa (DISCO Study) was a prospective observational cohort study that followed participants in KwaZulu-Natal, South Africa, transitioning to TLD. Our primary outcome of interest was clinically significant weight gain, defined as ≥10% increase from baseline to 48 weeks. Primary exposures of interest were (1) fruit intake (servings/week), (2) vegetable intake (servings/week), (3) fast food intake frequency, (4) fried food intake frequency, (5) sugar-sweetened beverage (SSB) intake frequency, and (6) physical activity (MET-min/week). We compared changes in each exposure for 48 weeks among those with and without clinically significant weight gain and fit logistic regression models to examine adjusted relationships between these exposures and weight gain.
resultsAmong 367 participants, the median age was 42 years, 78% were woman, and 18.0% experienced clinically significant weight gain during 48 weeks. The mean change in fruit intake was higher among participants with versus without clinically significant weight gain (0.21 servings/week [95% CI: -0.9 to 1.3] versus -1.07 servings/week [95% CI: -1.5 to -0.6], respectively) ( P = 0.015). However, no significant differences in other behaviors were observed and no dietary and activity behaviors correlated with weight change in multivariable regression models. DISCUSSION: Weight gain in people transitioning to TLD was not strongly linked to lifestyle. Interventions targeting diet and exercise may be unlikely to mitigate weight gain in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.